Advanced search
Publication Cover
Journal of Medical Economics Volume 23, 2020 - Issue 7
Submit an article Journal homepage
3,010
Views
34
CrossRef citations to date
0
Altmetric
Oncology

Patient characteristics and outcomes after ruxolitinib discontinuation in patients with myelofibrosis

John MascarenhasMedicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Correspondence[email protected]
,
Maneesha MehraStrategic Market Access, Janssen Global Services, LLC, Raritan, NJ, USA;
,
Jianming HeOncology-NJ based, Janssen Global Services, LLC, Raritan, NJ, USA; ORCID Iconhttp://orcid.org/0000-0002-5015-3713
ORCID Icon,
Ravi PotluriHEOR and Financial Modeling, SmartAnalyst Inc, New York, NY, USA;
&
Christina LoefgrenMyeloid Diseases, Janssen Global Services, LLC, Raritan, NJ, USA
Pages 721-727 | Received 29 Sep 2019, Accepted 05 Mar 2020, Published online: 31 Mar 2020

Citations (34)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (6)

Prithviraj Bose, Andrew T. Kuykendall, Carole Miller, Sandra Kurtin, Kyle Farina, Donald M. Harting, John O. Mascarenhas & Ruben A. Mesa. (2023) Moving beyond ruxolitinib failure in myelofibrosis: evolving strategies for second line therapy. Expert Opinion on Pharmacotherapy 24:9, pages 1091-1100.
Read now
Douglas Tremblay & John Mascarenhas. (2023) Pharmacotherapeutic advances for splenomegaly in myelofibrosis. Expert Opinion on Pharmacotherapy 24:5, pages 577-585.
Read now
James T. England & Vikas Gupta. (2022) Fedratinib: a pharmacotherapeutic option for JAK-inhibitor naïve and exposed patients with myelofibrosis. Expert Opinion on Pharmacotherapy 23:15, pages 1677-1686.
Read now
Julian A. Waksal, Claire N. Harrison & John O. Mascarenhas. (2022) Novel therapeutics and targets in myelofibrosis. Leukemia & Lymphoma 63:5, pages 1020-1033.
Read now
Julian A Waksal, Douglas Tremblay & John Mascarenhas. (2021) Clinical Utility of Fedratinib in Myelofibrosis. OncoTargets and Therapy 14, pages 4509-4521.
Read now
Douglas Tremblay & Ronald Hoffman. (2021) Emerging drugs for the treatment of myelofibrosis: phase II & III clinical trials. Expert Opinion on Emerging Drugs 26:4, pages 351-362.
Read now

Articles from other publishers (28)

John Mascarenhas, Marina Kremyanskaya, Andrea Patriarca, Francesca Palandri, Timothy Devos, Francesco Passamonti, Raajit K. Rampal, Adam J. Mead, Gabriella Hobbs, Joseph M. Scandura, Moshe Talpaz, Nikki Granacher, Tim C. P. Somervaille, Ronald Hoffman, Marielle J. Wondergem, Mohamed E. Salama, Gozde Colak, Jike Cui, Jean-Jacques Kiladjian, Alessandro M. Vannucchi, Srdan Verstovsek, Natalia Curto-García, Claire Harrison & Vikas Gupta. (2023) MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis. Journal of Clinical Oncology 41:32, pages 4993-5004.
Crossref
Ruben A. Mesa, Stacie Hudgens, Lysbeth Floden, Claire N. Harrison, Jeanne Palmer, Vikas Gupta, Donal P. McLornan, Mary F. McMullin, Jean‐Jaques Kiladjian, Lynda Foltz, Uwe Platzbecker, M. Laura Fox, Adam J. Mead, David M. Ross, Stephen T. Oh, Andrew Perkins, Michael F. Leahy, Samineh Deheshi, Rafe Donahue, Barbara J. Klencke & Srdan Verstovsek. (2023) Symptomatic benefit of momelotinib in patients with myelofibrosis: Results from the SIMPLIFY phase III studies . Cancer Medicine 12:9, pages 10612-10624.
Crossref
John Mascarenhas, Hiep Nguyen, Ashley Saunders, Louisa Oliver, Hannah Tomkinson, Richard Perry & Ali McBride. (2023) Defining ruxolitinib failure and transition to next-line therapy for patients with myelofibrosis: a modified Delphi panel consensus study. Future Oncology 19:11, pages 763-773.
Crossref
Helen T. Chifotides, Lucia Masarova & Srdan Verstovsek. (2023) SOHO State of the Art Updates and Next Questions: Novel Therapeutic Strategies in Development for Myelofibrosis. Clinical Lymphoma Myeloma and Leukemia 23:4, pages 219-231.
Crossref
Helen T. Chifotides, Prithviraj Bose & Srdan Verstovsek. (2022) Momelotinib: an emerging treatment for myelofibrosis patients with anemia. Journal of Hematology & Oncology 15:1.
Crossref
Dan Ouchi, Maria Giner-Soriano, Ainhoa Gómez-Lumbreras, Cristina Vedia Urgell, Ferran Torres & Rosa Morros. (2022) Automatic Estimation of the Most Likely Drug Combination in Electronic Health Records Using the Smooth Algorithm: Development and Validation Study. JMIR Medical Informatics 10:11, pages e37976.
Crossref
Julian A. Waksal & John Mascarenhas. (2022) Novel Therapies in Myelofibrosis: Beyond JAK Inhibitors. Current Hematologic Malignancy Reports 17:5, pages 140-154.
Crossref
Andrew T. Kuykendall, Qianxing Mo, David A. Sallman, Najla Al Ali, Onyee Chan, Seongseok Yun, Kendra L. Sweet, Eric Padron, Jeffrey E. Lancet & Rami S. Komrokji. (2022) Disease‐related thrombocytopenia in myelofibrosis is defined by distinct genetic etiologies and is associated with unique prognostic correlates. Cancer 128:19, pages 3495-3501.
Crossref
Aaron T. GerdsJason GotlibHaris AliPrithviraj BoseAndrew DunbarAmro ElshouryTracy I. GeorgeKrishna GundaboluElizabeth HexnerGabriela S. HobbsTania JainCatriona JamiesonPaul R. KaesbergAndrew T. KuykendallYazan MadanatBrandon McMahonSanjay R. MohanKalyan V. NadimintiStephen OhAnimesh PardananiNikolai PodoltsevLindsay ReinRachel SalitBrady L. SteinMoshe TalpazPankit VachhaniMartha WadleighSarah WallDawn C. Ward, Mary Anne BergmanCindy Hochstetler. (2022) Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network 20:9, pages 1033-1062.
Crossref
Claire N Harrison, Vikas K Gupta, Aaron T Gerds, Raajit Rampal, Srdan Verstovsek, Moshe Talpaz, Jean-Jacques Kiladjian, Ruben Mesa, Andrew T Kuykendall, Alessandro M Vannucchi, Francesca Palandri, Sebastian Grosicki, Timothy Devos, Eric Jourdan, Marielle J Wondergem, Haifa Kathrin Al-Ali, Veronika Buxhofer-Ausch, Alberto Alvarez-Larrán, Andrea Patriarca, Marina Kremyanskaya, Adam J Mead, Sanjay Akhani, Yuri Sheikine, Gozde Colak & John Mascarenhas. (2022) Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis. Future Oncology 18:27, pages 2987-2997.
Crossref
Ruben Mesa, Claire Harrison, Stephen T. Oh, Aaron T. Gerds, Vikas Gupta, John Catalano, Francisco Cervantes, Timothy Devos, Marek Hus, Jean-Jacques Kiladjian, Ewa Lech-Maranda, Donal McLornan, Alessandro M. Vannucchi, Uwe Platzbecker, Mei Huang, Bryan Strouse, Barbara Klencke & Srdan Verstovsek. (2022) Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis. Leukemia 36:9, pages 2261-2268.
Crossref
John O. Mascarenhas & Srdan Verstovsek. (2022) The clinical dilemma of JAK inhibitor failure in myelofibrosis: Predictive characteristics and outcomes. Cancer 128:14, pages 2717-2727.
Crossref
John Mascarenhas, Claire N Harrison, Jean-Jacques Kiladjian, Rami S Komrokji, Steffen Koschmieder, Alessandro M Vannucchi, Tymara Berry, Denise Redding, Laurie Sherman, Souria Dougherty, Lixian Peng, Libo Sun, Fei Huang, Ying Wan, Faye M Feller, Aleksandra Rizo & Srdan Verstovsek. (2022) Imetelstat in intermediate-2 or high-risk myelofibrosis refractory to JAK inhibitor: IMpactMF phase III study design. Future Oncology 18:22, pages 2393-2402.
Crossref
Douglas Tremblay & Ruben Mesa. (2022) Momelotinib for the treatment of myelofibrosis with anemia. Future Oncology 18:20, pages 2559-2571.
Crossref
Erika Morsia, Elena Torre, Antonella Poloni, Attilio Olivieri & Serena Rupoli. (2022) Molecular Pathogenesis of Myeloproliferative Neoplasms: From Molecular Landscape to Therapeutic Implications. International Journal of Molecular Sciences 23:9, pages 4573.
Crossref
Pankit Vachhani, Srdan Verstovsek & Prithviraj Bose. (2022) Disease Modification in Myelofibrosis: An Elusive Goal?. Journal of Clinical Oncology 40:11, pages 1147-1154.
Crossref
Helen T. Chifotides, Prithviraj Bose, Lucia Masarova, Naveen Pemmaraju & Srdan Verstovsek. (2022) SOHO State of the Art Updates and Next Questions: Novel Therapies in Development for Myelofibrosis. Clinical Lymphoma Myeloma and Leukemia 22:4, pages 210-223.
Crossref
Ronda Copher, Arianna Kee & Aaron Gerds. (2022) Treatment Patterns, Health Care Resource Utilization, and Cost in Patients with Myelofibrosis in the United States. The Oncologist 27:3, pages 228-235.
Crossref
Douglas Tremblay & Ruben Mesa. (2022) Novel treatments for myelofibrosis: beyond JAK inhibitors. International Journal of Hematology.
Crossref
Andrew T. Kuykendall, Libo Sun, John Mascarenhas, Jean-Jacques Kiladjian, Alessandro M. Vannucchi, Julia Wang, Qi Xia, Eugene Zhu, Faye Feller, Aleksandra Rizo, Jacqueline Bussolari, Ying Wan & Rami Komrokji. (2021) Favorable overall survival with imetelstat in relapsed/refractory myelofibrosis patients compared with real-world data. Annals of Hematology 101:1, pages 139-146.
Crossref
James England & Vikas Gupta. (2021) Novel therapies vs hematopoietic cell transplantation in myelofibrosis: who, when, how?. Hematology 2021:1, pages 453-462.
Crossref
John Mascarenhas, Aaron Gerds & Srdan Verstovsek. (2021) Paradigm shift: combination BET and JAK inhibition in myelofibrosis. Leukemia 35:12, pages 3361-3363.
Crossref
Nicolaus Kröger, Giulia Sbianchi, Tiarlan Sirait, Christine Wolschke, Dietrich Beelen, Jakob Passweg, Marie Robin, Radovan Vrhovac, Grzegorz Helbig, Katja Sockel, Eibhlin Conneally, Marie Thérèse Rubio, Yves Beguin, Jürgen Finke, Paolo Bernasconi, Elena Morozova, Johannes Clausen, Peter von dem Borne, Nicolaas Schaap, Wilfried Schroyens, Francesca Patriarca, Nicola Di Renzo, Zeynep Arzu Yeğin, Patrick Hayden, Donal McLornan & Ibrahim Yakoub-Agha. (2021) Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT. Leukemia 35:12, pages 3551-3560.
Crossref
Douglas Tremblay, Lukas Ronner, Nikolai Podoltsev, Jason Gotlib, Mark Heaney, Andrew Kuykendall, Casey O’Connell, Jamile M. Shammo, Angela Fleischman, Ruben Mesa, Abdulraheem Yacoub, Ronald Hoffman, Erin Moshier, Nicole Zubizarreta & John Mascarenhas. (2021) Ruxolitinib discontinuation in polycythemia vera: Patient characteristics, outcomes, and salvage strategies from a large multi-institutional database. Leukemia Research 109, pages 106629.
Crossref
Andrew T. Kuykendall & Rami S. Komrokji. (2021) JAK Be Nimble: Reviewing the Development of JAK Inhibitors and JAK Inhibitor Combinations for Special Populations of Patients with Myelofibrosis. Journal of Immunotherapy and Precision Oncology 4:3, pages 129-141.
Crossref
Aniket Bankar, Shabbir Alibhai, Elliot Smith, Dongyang Yang, Sarah Malik, Verna Cheung, Nancy Siddiq, Jaime Claudio, Andrea Arruda, Hubert Tsui, Jose‐Mario Capo‐Chichi, James A. Kennedy, Caroline McNamara, Hassan Sibai, Dawn Maze, Wei Xu & Vikas Gupta. (2021) Association of frailty with clinical outcomes in myelofibrosis: a retrospective cohort study. British Journal of Haematology 194:3, pages 557-567.
Crossref
Douglas Tremblay & John Mascarenhas. (2021) Next Generation Therapeutics for the Treatment of Myelofibrosis. Cells 10:5, pages 1034.
Crossref
Sangeetha Venugopal & John Mascarenhas. (2020) Novel therapeutics in myeloproliferative neoplasms. Journal of Hematology & Oncology 13:1.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.